Speaker: Prof Spyridonidis A. Regulatory T cells in hematology: Where do we stand? Thursday, December 7, 2023

Participants: Spyridonidis A, Triantafyllou e, Liga M, Christopoulou N, Sagiadinou E. Remote training on 22 Nov 2023 regarding Chain of Indentity, Apheresis Portal, Patient Scheduling and Aph. Product (ide-cel) collection and shipment requirements  Training certificate signed

Συμμετέχοντες: Μ. Λίγκα  , Δ. Τσοκάνας , Μ. Λυσσάνδρου , Ε. Σαγιαδινού  , Ε. Τριανταφύλλου , Δ. Κεφάλα, B, Ζαχαριουδάκη Β  , Χριστοπούλου Αναστασία  , Α. Σπυριδωνίδης  Συμμετοχή στο 34ο Πανελλήνιο Αιματολογικό Συνέδριο με την εργασια με τίτλο ''Συσχέτιση των επιπέδων IL-6...

Συμμετέχοντες: Μ. Λίγκα  , Δ. Τσοκάνας , Μ. Λυσσάνδρου , Ε. Σαγιαδινού  , Ε. Τριανταφύλλου , Δ. Κεφάλα, B, Ζαχαριουδάκη Β  , Χριστοπούλου Αναστασία  , Α. Σπυριδωνίδης  Συμμετοχή στο 34ο Πανελλήνιο Αιματολογικό Συνέδριο με την εργασια με τίτλο ''Σύγκριση του προπαρασκευαστικού...

Συμμετέχοντες (με ομιλία): Σπυριδωνιδης Α, Λίγκα Μ, Τσοκάνας Δ, Σαγιαδινού Ε. Διάρκεια: 2 ημέρες Τύπος: Δια ζώσης. Επισυναπτεται προγραμμα του συνεδρίου. 

Presenting author (poster session): Sagiadinou E Participants: Smaili M, Aggelaki V, Kostoglou M, Tsima M, Christopoulou A, Koumouli A, Manolis A Κepetzis S, Kosteas P, Papatheodoridis G, Spyridonidis A. Title: Donor specific requests of donors that reside in a different country as the one...

Βρείτε επισυναπτόμενη την εκπαιδευτικη παρουσίαση του Καθ. Αλέξανδρου Σπυριδωνίδη Transplant in Ph- B ALL στο 5ο Εκπαιδευτικό Σεμινάριο στη Μεταμόσχευση Μυελού των Οστών και τις Κυτταρικές Θεραπείες: Απόψεις και Αντιπαραθέσεις, 12-13 Μαίου 2023, Αθήνα, Ξενοδοχείο Crowne Plaza Ομιλητής: Καθ. Α Σπυριδωνίδης Συμμετέχοντες:  Moνάδα Μεταμόσχευσης Μυελού...

See the attached the educational slides of Prof Spyridonidis presentation at 49th EBMT annual meeting, Paris 2023_GVHD prophylaxis in matched sibling donor transplant_PTCY_Spyridonidis

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 40 mins Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial

49 Annual Meeting of the EBMT - 23-26 April, 2023, Paris France Relapse remains a major cause of failure after allogeneic hematopoietic cell trnaplantation (allo-HCT). Prophylactic donor lymphocyte infusion (pDLI) could be used to reduce relapse. However, its widespread application has been restricted...

49 Annual Meeting of the EBMT - 23-26 April, 2023, Paris France Though a randomized study suggested the benefit of in vivo T-cell depletion (TCD) as Graft versus Host Disease (GvHD) prophylaxis in matched sibling donor (MSD) allogeneic hematopoietic cell transplantation...

March 19–March 22, 2023 Munich, Germany https://www.dropbox.com/s/10uojri60ijyazs/Leukemia%20MUnich%20selected.pptx?dl=0

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 40 mins The optimal selection of patients with acute myeloid leukemia (AML) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an area of research that continues to evolve.1 For patients with favorable-risk AML who achieve...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 35 Mins Understanding how genetic variants impact molecular phenotypes is a key goal of functional genomics, currently hindered by reliance on a single haploid reference genome. Here, we present the EN-TEx resource of 1,635 open-access datasets...

1. Lesson Plan_Pre-clinical studies design 2. Pre-clinical studies - An overview - Ariel Angel 11.2022 3. Tech Transfer

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration:40mins https://www.bloodtransfusion.it/bt/article/view/332

https://www.cancertherapyadvisor.com/home/cancer-topics/hematologic-cancers/hematologic-cancers-treatment-regimens/leukemia-treatment-regimens-acute-lymphoblastic-leukemia-all/ NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas Duration: 40mins Axicabtagene ciloleucel is an engineered autologous anti-CD19 chimeric antigen receptor T cell therapy being developed for patients with refractory aggressive B-cell lymphoma. The product is manufactured in a central facility from cellular starting material containing...